The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379
Open accessAbstract
Adult Mesenchymal Stem Cells (MSCs) have a well-established tumor-homing capacity, highlighting potential as tumor-targeted delivery vehicles. MSCs secrete extracellular vesicle (EV)-encapsulated microRNAs, which play a role in intercellular communication. The aim of this study was to characterize a potential tumor suppressor microRNA, miR-379, and engineer MSCs to secrete EVs enriched with miR-379 for in vivo therapy of breast cancer. miR-379 expression was significantly reduced in lymph node metastases compared to primary tumor tissue from the same patients. A significant reduction in the rate of tumor formation and growth in vivo was observed in T47D breast cancer cells stably expressing miR-379. In more aggressive HER2-amplified HCC-1954 cells, HCC-379 and HCC-NTC tumor growth rate in vivo was similar, but increased tumor necrosis was observed in HCC-379 tumors. In response to elevated miR-379, COX-2 mRNA and protein was also significantly reduced in vitro and in vivo. MSCs were successfully engineered to secrete EVs enriched with miR-379, with the majority found to be of the appropriate size and morphology of exosomal EVs. Administration of MSC-379 or MSC-NTC cells, or EVs derived from either cell population, resulted in no adverse effects in vivo. While MSC-379 cells did not impact tumor growth, systemic administration of cell-free EVs enriched with miR-379 was demonstrated to have a therapeutic effect. The data presented support miR-379 as a potent tumor suppressor in breast cancer, mediated in part through regulation of COX-2. Exploiting the tumor-homing capacity of MSCs while engineering the cells to secrete EVs enriched with miR-379 holds exciting potential as an innovative therapy for metastatic breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Brien et al. reported that mesenchymal stem cells (MSC)-derived exosomes containing miR-379 were shown to have a therapeutic effect on breast cancer, with significantly reduced tumor growth rates in T47D breast cell line expressing miR-379 [51].”
From The Therapeutic Potential and Clinical Significance of Exosomes as Carriers of Drug Delivery System (2022) · cites this paper as [51]
Citations
Cites
1 retracted
RETRACTED: Micro RNA ‐379 suppresses osteosarcoma progression by targeting PDK 1
Li, Z., Shen, J., Chan, M. T. V., & Wu, W. K. K. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12966 · Cited by 60
RetractedAnalysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
miR-15 and miR-16 induce apoptosis by targeting BCL2
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506654102 · Cited by 3,579
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
Costa-Silva, B., Aiello, N. M., Ocean, A. J., Singh, S., Zhang, H., Thakur, B. K., Becker, A., Hoshino, A., Mark, M. T., Molina, H., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3169 · Cited by 2,692
Research works printed but not linked: 2
- Khan S, Brougham CL, Ryan J, Sahrudin A, O’Neill G, Wall D, et al. miR-379 regulates cyclin B1 expression and is decreased in breast cancer. PLoS ONE. 2013;8:e68753. · DOI
- Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, et al. Monocyte chemotactic protein-1 (MCP-1) secreted by primary breast tumors stimulates migration of Mesenchymal Stem Cells (MSCs). Clin Cancer Res. 2007;13:5020–7. · DOI
Cited by
Sorted by citations
Items 201–215 of 215
Aydemir, D., & Ulusu, N. N. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_219
Wang, X., Jiang, L., & Liu, Q. (2022) · TigerPrints (Clemson University) · doi:10.6084/m9.figshare.20025768
Wang, X., Jiang, L., & Liu, Q. (2022) · TigerPrints (Clemson University) · doi:10.6084/m9.figshare.20025771
Exosomes in cancer therapeutic delivery
Karmakar, A., Khairnar, Y. N., & Kumar, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-29052-7.00015-5
Gilligan, K., Treacy, O., O’Neill, C. P., McCarthy, E. C., McDermott, E. A., Mammen, E., Dockery, P., Ryan, A. E., & Dwyer, R. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.28.635343
Self-citationSalehi, R., Wyse, B. A., Asare-Werehene, M., Esfandiarinezhad, F., Abedini, A., Pan, B., Urata, Y., Gutsol, A., Viñas, J. L., Jahangiri, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22618388
The potential of stem cells in breast cancer therapy: A review
Liu, Z., & Wang, D. (2026) · Medicine · doi:10.1097/md.0000000000048829
The updated role of exosomes in cancer diagnosis and therapy
Huang, X., Huang, Y., Wei, X., & Xu, Y. (2026) · Discover Oncology · doi:10.1007/s12672-026-05193-9
Exosome-based therapy for breast cancer treatment
Madhur, K., Shama, A., Kumar, S. N., Mohite, S., Mansaa, S., Shweta, R., & Sant, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43826-4.00015-4
Exosomes as emerging biomarkers and therapeutic platforms: From biology to clinical translation
Das, A., Chowdhury, S., Kar, K., Chakraborty, P., & Sarkar, S. (2026) · Biomaterials and Living Medicine for Pharmaceutics · doi:10.1016/j.bioliv.2026.100003
Tegegne, B. A., Belew, H., Teffera, Z. H., Belayneh, M., Abebaw, D., Fikrie, M., Jemal, M., Baylie, T., Tadesse, F., Wondm, S. A., et al. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04396-y
Targeting the tumor vasculature using mesenchymal stem cells in cancer therapy: New perspectives
Sikander, M., Malik, S., Yallapu, M. M., & Chauhan, S. C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27731-3.00002-4
Mkabaah, L. B., McGovern, D., Kerin, E. P., Butler, T. O., Richard, V., Lowery, A., & Kerin, M. J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167345
Self-citationEngineered exosomes for breast cancer immunotherapy: Emerging strategies and translational potential
Orooji, N., Ghasemian-Irani, M., Salari, N., Eskandari, T., Shams, M., Razavi, F. T., & Haghmorad, D. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102822
Metadata
- Authors
- O’Brien, K. P., Khan, S., Gilligan, K. E., Zafar, H., Lalor, P., Glynn, C., O’Flatharta, C., Ingoldsby, H., Dockery, P., De Bhulbh, A., Schweber, J. R., St John, K., Leahy, M., Murphy, J. M., Gallagher, W. M., O’Brien, T., Kerin, M. J., & Dwyer, R. M.
- Affiliations
- Ollscoil na Gaillimhe – University of Galway (IE)
- University Hospital Galway (IE)
- University College Dublin (IE)
- Corresponding author
- Dwyer, R. M.
- ORCID
- Venue
- Oncogene
- Published
- 2018-01-25
- Volume
- 37
- Issue
- 16
- Pages
- 2137-2149
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2793133729
- Cited by
- 215
- References
- 54
- Citations by year
- 2026: 11 · 2025: 23 · 2024: 21 · 2023: 38 · 2022: 41 · 2021: 33 · 2020: 29 · 2019: 12 · 2018: 7
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Arrow@dit (Dublin Institute of Technology) (acceptedVersion)
- ARAN (University of Galway Research Repository) (Ollscoil na Gaillimhe – University of Galway) (acceptedVersion, cc-by-nc-nd)
- ARAN (University of Galway Research Repository) (Ollscoil na Gaillimhe – University of Galway) (acceptedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- mesenchymal stem cells, extracellular vesicles, tumor-targeted delivery, breast cancer, tumor suppressor microRNA, cyclooxygenase-2, HER2-amplified breast cancer, lymph node metastasis, cell-free therapy, exosomes
- MeSH terms
- Extracellular Vesicles, Animals, Breast Neoplasms, Cells, Cultured, Drug Compounding, Female, Humans, Lymphatic Metastasis, Mice, Inbred BALB C, Mice, Nude, Neoplasm Metastasis, Genetic Therapy, Gene Expression Regulation, Neoplastic, Drug Delivery Systems, Xenograft Model Antitumor Assays, MicroRNAs, Therapies, Investigational, Mesenchymal Stem Cell Transplantation, Mice, Adult Stem Cells, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
